Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug122 | AN69-Oxiris Wiki | 0.58 |
| drug4444 | Toraymyxin PMX-20R (PMX Cartridge) Wiki | 0.58 |
| drug123 | AN69-Standard Wiki | 0.58 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug392 | Assessment of coagulopathy, Platelets activation and Platelets-Neutrophils interplay Wiki | 0.58 |
| drug314 | Angiotensin II Wiki | 0.41 |
| drug4698 | Vitamin Super B-Complex Wiki | 0.33 |
| drug2804 | Nitazoxanide Wiki | 0.15 |
| drug4102 | Standard of Care Wiki | 0.09 |
| drug3195 | Placebo Wiki | 0.02 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| D019446 | Endotoxemia NIH | 0.58 |
| D012769 | Shock, NIH | 0.44 |
| D004211 | Disseminated Intravascular Coagulation NIH | 0.26 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| HP:0005521 | Disseminated intravascular coagulation HPO | 0.26 |
| HP:0100806 | Sepsis HPO | 0.18 |
| HP:0001919 | Acute kidney injury HPO | 0.11 |
Navigate: Correlations HPO
There are 3 clinical trials
Knowing the dramatic increase in thrombin generation during sepsis, our research hypothesis is that AMPK-induced ACC phosphorylation in platelets is increased and that this might modulate platelets metabolism and more particularly platelets inflammatory mediators content, coming from AA and lipids.
Description: ACC phosphorylation on Ser79 (phosphoACC) in platelets of patients will be assessed using western blotting. Results will be expressed in arbitrary units (A.U). A signal above 0.5 A.U. has already been shown to be above 2 standard deviation in a healthy population.
Measure: Platelets Acetyl-CoA Carboxylase phosphorylation rate Time: At the time of inclusionDescription: Sepsis severity will be assessed using the SOFA score (Sepsis-related Organ Failure Assessment). Range from 0( less severe) to 24 (more severe).
Measure: Sepsis severity Time: At the time of inclusionDescription: Sepsis severity will be assessed using the APACHE II score) Acute Physiology And Chronic Health Evaluation) Range 0 (less severe) to 299 (more severe).
Measure: Sepsis severity Time: At the time of inclusionDescription: Platelet function will be assessed using platelets aggregometry. The Aggregation (in AU), the maximum height of the curve during the measurement period will be assessed.
Measure: Platelet function assessment Time: At the time of inclusionDescription: Platelet function will be assessed using platelets aggregometry. Area Under the aggregation Curve (AUC) will be assessed and recorded as Units or U.
Measure: Platelet function assessment Time: At the time of inclusionDescription: Platelet function will be assessed using platelets aggregometry. Velocity (in AU/min), the maximum slope of the curve will be assessed.
Measure: Platelet function assessment Time: At the time of inclusionDescription: D-Dimers (ng/ml)
Measure: Thrombin generation marker rate Time: At the time of inclusionDescription: Urinary Thrombin-antithrombin complex (ng/mL)
Measure: Thrombin generation marker rate Time: At the time of inclusionDescription: Tubulin acetylation will be assessed using western blotting. Results will be expressed in arbitrary units (A.U).
Measure: Tubulin acetylation rate Time: At the time of inclusionDescription: Total platelets lipid content and composition will be assessed using metabolomics approach by Mass Spectrometry. Fold-change estimates and corresponding P values were derived from regression models for each lipid species and each predictor. To control for multiple testing, all P values will be further adjusted for Benjamini-Hochberg false discovery rate (FDR), with a FDR <0.05 considered statistically significant
Measure: Total platelets lipid content and composition Time: At the time of inclusionDescription: Myeloperoxidase MPO (ng/mL)
Measure: Neutrophils extracellular trap formation Time: At the time of inclusionDescription: Citrulinated Histon 3 H3-Cit (ng/mL)
Measure: Neutrophils extracellular trap formation Time: At the time of inclusionDescription: Soluble CD62P (ng/mL)
Measure: Platelets activation Time: At the time of inclusionDescription: PaO2/FiO2
Measure: Respiratory failure Time: At the time of inclusion and through study completion up to day 30Prospective, observational, clinical investigation of PMX cartridge use in COVID 19 patients with septic shock
Septic shock continues to exert a large economic burden around the world. Several developments have occurred that lead to the current study. First, angiotensin II is the newest FDA approved vasopressor agent indicated for use in vasodilatory shock. Several subgroups from the approval trial have indicated that angiotensin II may confer a survival benefit in certain conditions, including those patients requiring continuous renal replacement therapy, those with altered angiotensin I: angiotensin II ratios, and most recently, those with elevated renin levels (which may serve as a surrogate for dysfunctional angiotensin 1: angiotensin II ratios). This open-label, sequential period pilot study will evaluate angiotensin II and biomarker response (renin) in the treatment of septic shock.
Description: Plasma renin levels will be measured from blood collected at baseline, 24 hours, and at shock resolution. Additionally, a 3-hour measurement will be included in the angiotensin II arm.
Measure: Change in Plasma Renin Levels Time: Until shock resolution, up to 14 days (at baseline, 3 hours, 24 hours, and shock resolution, up to 14 days)Description: Cystatin C, NGAL will be measured from blood collected at baseline, 24 hours, and at shock resolution.
Measure: Change in Renal Biomarkers Time: Until shock resolution, up to 14 days (at baseline, 24 hours, and shock resolution, up to 14 days)Description: Time from enrollment to discontinuation of catecholamines
Measure: Time to discontinuation of catecholamines Time: Until shock resolution, up to 14 daysDescription: Number of days in the intensive care unit (ICU).
Measure: ICU Length of Stay Time: From enrollment to ICU discharge, up to 28 days following enrollmentDescription: Assessment of all-cause mortality within hospital admission
Measure: In-hospital mortality Time: Up to 3 months following enrollmentDescription: Days free of renal replacement therapy from enrollment up to day 28
Measure: Renal replacement therapy-free days Time: Within 28 days of enrollmentDescription: Incidence of venous thromboembolism, arrhythmia, extremity hypoperfusion, delirium, new ischemic event, new infection
Measure: Safety outcomes Time: Up to 72 hours following shock resolution, no longer than 17 days from enrollmentAlphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on December 13, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports